3 hours ago
1
Inna Kot/iStock via Getty Images
The FDA staffers on Wednesday cited efficacy issues related to a combination regimen involving brexpiprazole, an antipsychotic medication developed by Otsuka Pharma (OTCPK:OTSKY) and H. Lundbeck (OTCPK:HLBBF) for post-traumatic stress disorder (PTSD).
Issuing briefing documents ahead of a meeting of the
English (US) ·